Beta Bionics (NASDAQ:BBNX) CFO Sells 6,675 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) CFO Stephen Feider sold 6,675 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $127,559.25. Following the completion of the transaction, the chief financial officer directly owned 159,378 shares of the company’s stock, valued at approximately $3,045,713.58. The trade was a 4.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stephen Feider also recently made the following trade(s):

• On Monday, June 29th, Stephen Feider sold 4,896 shares of Beta Bionics stock. The stock was sold at an average price of $17.03, for a total value of $83,378.88.
• On Friday, June 26th, Stephen Feider sold 5,104 shares of Beta Bionics stock. The shares were sold at an average price of $17.05, for a total value of $87,023.20.

Beta Bionics Stock Up 2.6%

Shares of BBNX traded up $0.50 on Thursday, hitting $19.92. The company’s stock had a trading volume of 1,403,531 shares, compared to its average volume of 1,146,397. The firm’s fifty day moving average price is $17.03 and its 200-day moving average price is $13.57. Beta Bionics, Inc. has a fifty-two week low of $8.80 and a fifty-two week high of $32.71. The firm has a market capitalization of $896.20 million, a price-to-earnings ratio of -12.07 and a beta of 3.37.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. The firm had revenue of $32.01 million for the quarter. As a group, equities analysts predict that Beta Bionics, Inc. will post -2.1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Beta Bionics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Perceptive Advisors LLC lifted its position in Beta Bionics by 39.8% during the first quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after acquiring an additional 240,000 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Beta Bionics during the second quarter worth $52,340,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Beta Bionics in the fourth quarter valued at about $40,437,000. Bruce & Co. Inc. bought a new stake in shares of Beta Bionics in the first quarter valued at about $5,518,000. Finally, Y Intercept Hong Kong Ltd grew its stake in shares of Beta Bionics by 4,236.8% in the first quarter. Y Intercept Hong Kong Ltd now owns 485,854 shares of the company’s stock valued at $4,868,000 after acquiring an additional 474,651 shares in the last quarter.

Wall Street Analysts Forecast Growth

BBNX has been the topic of several research reports. Bank of America cut their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a research report on Monday, May 18th. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. UBS Group assumed coverage on Beta Bionics in a research report on Tuesday, July 28th. They set a “buy” rating and a $22.00 price objective for the company. William Blair initiated coverage on Beta Bionics in a report on Friday, August 21st. They set a “market perform” rating for the company. Finally, Truist Financial lifted their target price on Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.10.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.